You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent and selective irreversible PPARγ antagonist (IC50 = 1 nM). Displays > 800-fold selectivity for PPARγ over PPARα and PPARδ. Blocks transcriptional activity of PPARγ in vitro and inhibits rosiglitazone-induced adipogenesis.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 277.67. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.6 mL||18.01 mL||36.01 mL|
|5 mM||0.72 mL||3.6 mL||7.2 mL|
|10 mM||0.36 mL||1.8 mL||3.6 mL|
|50 mM||0.07 mL||0.36 mL||0.72 mL|
References are publications that support the biological activity of the product.
Lee et al (2002) T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonist of biochemical and cellular activities. J.Biol.Chem. 277 19649 PMID: 11877444
Rockwell and Kaminski (2004) A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J.Pharmacol.Exp.Ther. 311 683 PMID: 15284281
Schaefer et al (2005) Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. 65 2251 PMID: 15781638
If you know of a relevant reference for T 0070907, please let us know.
View Related Products by Product Action
Keywords: T 0070907, T 0070907 supplier, potent, selective, PPARγ, PPARgamma, antagonists, Peroxisome, Proliferator-activating, Receptors, T0070907, 2301, Tocris Bioscience
4 Citations for T 0070907
Citations are publications that use Tocris products. Selected citations for T 0070907 include:
Bullers et al (2014) The human tissue-biomaterial interface: a role for PPARγ-dependent glucocorticoid receptor activation in regulating the CD163+ M2 macrophage phenotype. Tissue Eng Part A 20 2390 PMID: 24548290
Hamtiaux et al (2012) The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer 12 92 PMID: 22429826
Kassotis et al (2017) Characterization of Adipogenic Chemicals in Three Different Cell Culture Systems: Implications for Reproducibility Based on Cell Source and Handling. Sci Rep 7 42104 PMID: 28176856
Hamtiaux et al (2011) Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PLoS One 6 e26823 PMID: 22046372
Do you know of a great paper that uses T 0070907 from Tocris? Please let us know.
Reviews for T 0070907
Average Rating: 5 (Based on 1 Review.)
Have you used T 0070907?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
HL-1 cardiomyocytes were incubated with T 0070907 (1 µM) for 30 min prior to addition of 15 µM 15d-PGJ2 for 30 min. Preincubation of cells with T 0070907 completely abolished activation of p42/44 MAPK indicating involvement of PPAR gamma in cellular signalling in response to 15d-PGJ2.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.